CLAIMS

1. Use of Cannabidivarin (CBDV) in the manufacture of a medicament for the treatment of epilepsy, wherein the CBDV is present as an isolated cannabinoid.

2. The use according to claim 1, wherein the CBDV is formulated for oral delivery.

3. The use according to any of the preceding claims, for the treatment of a generalised seizure or a temporal lobe seizure.

4. The use according to any of the preceding claims, wherein the CBDV is in combination with cannabidiol (CBD).

5. The use according to any of the preceding claims, wherein the CBDV is used in combination with a standard anti-epileptic drug.